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Abstract
Purpose: Pubertal dynamics plays an important role in physical and psychological development of children and
adolescents. We aim to provide reference ranges of plasma testosterone in a large longitudinal sample. Furthermore, we
describe a measure of testosterone trajectories during adolescence that can be used in future investigations of
development.
Methods: We carried out longitudinal measurements of plasma testosterone in 2,216 samples obtained from 513 males (9
to 17 years of age) from the Avon Longitudinal Study of Parents and Children. We used integration of a model fitted to each
participant’s testosterone trajectory to calculate a measure of average exposure to testosterone over adolescence. We
pooled these data with corresponding values reported in the literature to provide a reference range of testosterone levels in
males between the ages of 6 and 19 years.
Results: The average values of total testosterone in the ALSPAC sample range from 0.82 nmol/L (Standard Deviation [SD]:
0.09) at 9 years of age to 16.5 (SD: 2.65) nmol/L at 17 years of age; these values are congruent with other reports in the
literature. The average exposure to testosterone is associated with different features of testosterone trajectories such as
Peak Testosterone Change, Age at Peak Testosterone Change, and Testosterone at 17 years of age as well as the timing of
the growth spurt during puberty.
Conclusions: The average exposure to testosterone is a useful measure for future investigations using testosterone
trajectories to examine pubertal dynamics.
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Introduction
Puberty (activation of the hypothalamic-pituitary-gonadal axis)
and adolescence (maturation of adult social and cognitive
behaviours) are intertwined [1]. Variations in pubertal trajectories
have been associated with those in physical and behavioral
development [2]. For example, an earlier onset of puberty predicts
a higher body mass index and central fat-mass in 19-year old men
[3]. Early pubertal timing and faster pubertal tempo appear to be
associated with depressive symptoms in male adolescents [4].
The activation of the hypothalamic-pituitary-gonadal (HPG)
axis stimulates the male testes and, in turn, increases production of
testosterone [5,6]. In males, testosterone is a sex steroid that plays
a critical role in numerous pubertal processes, including genital
growth [7], change in body composition [8], and maturation of the
brain [9,10]. Given testosterone’s crucial role in puberty, its
dynamics may be driving associations previously ascribed to
pubertal timing and tempo [4], thus underscoring the importance
of studying testosterone trajectories in relation to healthy and
abnormal development.
A number of human studies have investigated changes in
testosterone levels throughout the lifespan of males. We reviewed
the literature for reports that provided normal ranges of total
testosterone during male adolescence, pooled together data from
the five studies identified [11–15], and report the weighted values.
Of the five studies included, one (Schnakenburg, 1980) used
plasma and the other four studies used serum to quantify
testosterone levels. The ethnicity of participants was often not
described. One of the studies was conducted in the United States
(Lee, 1974), and the other four in Europe. Longitudinal measures
of testosterone are a pre-requisite for investigating testosterone
trajectories in adolescent males. To this end, we quantified levels
of total testosterone from longitudinal samples in typically
developing males from the Avon Longitudinal Study of Parents
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and Children (ALSPAC). We also include ranges for sex hormone
binding globulin (SHBG) and the calculated free and bioavailable
fractions of testosterone, as these are of interest when studying the
effect of testosterone on the brain and body. The total testosterone
describes the amount of hormone produced by the body whereas
the bioavailable testosterone refers to the amount of testosterone
capable of crossing cell membranes [16]. Finally, we describe a
measure of average exposure to testosterone throughout adoles-
cence derived from participants’ testosterone trajectories, and
examine the trajectories in context of the adolescent growth spurt,
as indexed by Age at Peak Height Velocity (APHV), and several
characteristics of the testosterone trajectories.
Methods
The Avon Longitudinal Study of Parents and Children
We used blood samples obtained from participants in the Avon
Longitudinal Study of Parents and Children (ALSPAC), a birth
cohort that recruited 14,541 pregnant women resident in Avon,
United Kingdom with an expected delivery date between April
1991 and December 1992. Since then, the children and their
parents have been studied extensively with longitudinal data
available from self-administered questionnaires sent to their
homes, linkages to medical records, and through clinical
examinations carried out during study visits [17]. Ethical approval
for ALSPAC was obtained from the ALSPAC Ethics and Law
Committee and the Local Research Ethics Committees. Data used
for this submission will be made available on request to the
ALSPAC executive committee (alspac-exec@bristol.ac.uk). The
ALSPAC data management plan describes in detail the policy
regarding data sharing, which is through a system of managed
open access (http://www.bristol.ac.uk/alspac/researchers/data-
access/documents/alspac-data-management-plan.pdf).
Blood samples were taken at select visits over the course of the
study, roughly at the following years of age: 7, 9, 11, 13, 15, and
17. We obtained and analyzed sex steroids from the blood samples
of a subset of 513 male participants who had been recruited for
further study using magnetic resonance imaging (MRI). We did
not utilize blood samples from the 7-year visit, as most individuals
are likely to have very low or undetectable levels of sex steroids at
this age. All participants had a maximum of five and a minimum
of three blood samples across these five visits (5 samples: n = 232; 4
samples: n = 213; 3 samples: n = 68).
Quantification of Testosterone and Sex Hormone Binding
Globulin
The blood samples, in the form of lithium heparin plasma, were
sent from ALSPAC to the Biomarker Core Laboratory at The
Pennsylvania State University, where enzyme-linked immunosor-
bent assays were conducted - using commercially available kits - to
determine plasma concentrations of testosterone (EIA-1559; DRG
International; Springfield, New Jersey, USA) and SHBG
(IB79131; Immuno-Biological Laboratories, Inc.; Minnesota,
MN, USA). For testosterone and SHBG, the sample test volumes
were 25 ul and 10 ul, respectively. The assays had lower limits of
sensitivity of 0.28 nmol/L (testosterone) and 0.77 nmol/L
(SHBG), with average inter- and intra-assay coefficients of
variation less than 10%. The assay sensitivity is calculated by
subtracting two standard deviations from the mean of 20 identical
runs of the zero standard.
For quality-control purposes, 10% of participant samples were
tested in duplicate, balanced across plates while the rest of the
samples were run in singlet to increase efficiency. All samples from
a participant were run on the same plate. Of the samples run in
duplicate, test values that varied by more than 5% were subject to
repeat testing. The first-well values from all samples are used in
data analyses for consistency. For testosterone samples that yielded
undetectable hormone values or values below the lower limit of
sensitivity for the assay (n = 199; 8.9% of all samples; 136 from the
9-year visit, 58 from the 11-year visit, and 5 from the 13-year visit),
we used the lower bound value of the detectable range for the
assay: 0.28 nmol/L.
Effects of Age and Circadian Rhythm on Testosterone
Since testosterone demonstrates a circadian rhythm [18] and
the time of venipuncture was not standardized across study
participants due to logistical reasons, we used multilevel modeling
to predict total testosterone measurements at a standard time of
day (12 PM). The effect of time of venipuncture on testosterone
levels differed across age groups; therefore separate models were
fitted for each visit (9, 11, 13, 15 and 17 years). In each of these
models age was included as a continuous variable (note that age
varied very little between participants at each visit – see Table 1)
and time of sample was included as a categorical variable split into
half-hour increments. The models fitted for ages 15 and 17 also
included age squared, as there was evidence of a quadratic effect of
age on testosterone. We assessed model fit by comparing the
observed with the predicted values, and the best fitting models
were chosen from which to obtain predicted values of testosterone.
There were clear differences between observed and predicted
values at age 13 indicating that models for age 13 did not fit well.
We hypothesized that this was because age 13 is the time when
puberty had begun in some but not all boys. We therefore fit the
age 13 model separately for those who had and had not reached
age at peak height velocity, which is a proxy for pubertal onset
[19]. In these models, time of sample was again modeled as a
categorical variable using half-hour increments. Age was not
explicitly included in these models since participants were split
based on whether they reached their age of peak height velocity, a
variable that correlates with chronological age [19,20].
Measure of Average Exposure to Testosterone
Throughout Adolescence
We calculated a measure of average exposure to testosterone
throughout adolescence for participants based on the area under
the curve of their testosterone trajectory. The longitudinal
measurements of total testosterone and the respective age in
months at venipuncture were used to plot the participant’s total
testosterone values during his childhood and adolescence. The
shape preserving spline-interpolation function from the MATLAB
Basic Fitting toolbox (Mathworks, Natick, MA USA) was used to
generate a curve through the data-points. The area under the
curve (integral) was calculated, with respect to ground, for the
section of the spline between the first and last blood sample. This is
similar to the method applied by Pruessner and colleagues in
context of cortisol sampled at multiple points within an hour [21].
To accommodate variations between participants’ age ranges from
the first to the last visit, we standardized this variable by dividing
the integral value for each participant by their exact age range (in
months) between the first and last visit. The resulting value is an
estimate of the arithmetic mean of monthly measurements, if
testosterone were sampled each month throughout the partici-
pant’s adolescence.
Testosterone Trajectories
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Growth Spurt and Characteristics of Testosterone
Trajectories
For each participant, we calculated Age at Peak Height Velocity
(APHV) using up to nine height measurements collected at each
ALSPAC visit, from 7 through 17 years of age, as described
previously [19]. Briefly, the height data for each participant are
fitted with a cubic spline from the Basic Fitting Toolbox in
MATLAB (Mathworks, Natick, MA USA). Taking the derivative
of the height curve gives us the growth curve, from which we
ascertain the Peak Height Velocity and the corresponding age (in
months) when this occurs.
We estimated the analogous measures for testosterone data,
Peak Testosterone Change and Age at Peak Testosterone Change,
by applying the same spline method. This calculation was
restricted to participants who had blood collected at all five visits
(n = 232), given that fewer than five data-points would likely lead
to imprecise estimates.
Free and Bioavailable Testosterone
To calculate levels of free testosterone and to derive values of
bio-available testosterone, we used the equation (Total Testoster-
one = Free Testosterone+SHBG Bound Testosterone+Albumin
Bound Testosterone) in conjunction with the (measured) SHBG
and (estimated) albumin concentrations as described by So¨derga˚rd
[22].
Statistics
We used Stata version 12.1 (StataCorp LP, College Station,
TX) for multilevel modeling to adjust values of Total Testosterone.
Other statistical analyses used JMP 9 for Macintosh (SAS Institute,
Inc., Cary, NC): simple linear regression was used to relate the
measure of average testosterone exposure to APHV, Age at Peak
Testosterone Change, Peak Testosterone Change, and Total
Testosterone at 17 years. In order to visualize participants’
testosterone trajectories and to investigate whether they varied in
form between those with higher or lower average testosterone, we
divided participants into quintiles based on the measure of average
exposure to testosterone and graphed trajectories separately for
each quintile.
Review of Published Data
To compare our results with the published values of testoster-
one, we reviewed the literature and included studies that reported
either a mean (with standard deviation) or a median (with range)
for values of total testosterone measured from plasma or serum
samples in males between the ages of 6 and 20 years. Note that the
type of a sample (plasma vs. serum) may not affect measured
values; we have conducted a pilot study using blood samples from
10 adult participants (5 female) to compare testosterone values
measured in serum and plasma (sodium heparin, or lithium
heparin, or EDTA) and found that these values showed
correlations of .0.99 across the different media.
To identify such studies, we conducted a PubMed search in
January 2012, using combinations of the following search terms:
‘testosterone’, ‘androgen’, ‘normal’, ‘reference range’, ‘adoles-
cence’, ‘childhood’, ‘serum’, and ‘plasma’. We excluded studies for
the following reasons: presenting data in a graph without an
accompanying table, presenting data in subgroups of large age-
ranges (greater than 2-year intervals), or reporting reference
ranges for salivary testosterone or free testosterone without total
testosterone. Furthermore, within the selected studies, we included
only those age subgroups containing at least 10 participants.T
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First, we standardized the units for total testosterone into
nanomoles per liter using a conversion factor where necessary
(1 ng/mL = 3.467 nmol/L). For studies reporting median and
range, we used methods described by Hozo and colleagues to
estimate the mean and standard deviation (SD) [23]. When
pooling data across studies for each age subgroup across studies,
we used equations from Borenstein and colleagues to compute the
weighted mean and corresponding standard deviation [24].
Results
ALSPAC: Comparing the full cohort and the subsample
The supplementary table (Table S1) shows a comparison
between the subsample of 513 males included in this study and
the rest of the ALSPAC males who survived to at least 1 year of
age (n = 7024). The subsample differs from the full sample on a
number of variables in a manner consistent with being from
families with a higher parental education. Similar pattern of
attrition have been observed in other studies [25].
ALSPAC: Testosterone levels
The models we fitted to remove the effect of circadian rhythm
explained 1.7%, 9.5%, 5.8%, and 6.3% of the variance in total
testosterone at the 9, 11, 15 and 17-year visits, respectively.
Models for the 13-year visit were fitted separately for participants
who had not yet reached APHV and those that had passed APHV;
the variance explained was 17.3% and 22.1%, respectively. Note
that the relatively high proportion of variance in the unadjusted
levels of testosterone during the 13-year old visit is due to the
combination of rising testosterone levels and morning-afternoon
sampling schedule in this visit (see Discussion for details). Time of
sample explained less than 0.1% of the variance in the (time)
adjusted testosterone values at each visit, indicating that the
modeling to remove effects of circadian rhythm was successful.
Table 1 provides descriptive statistics for the distributions of
age, time at venipuncture, and concentrations of unadjusted and
adjusted total testosterone, SHBG, free testosterone and bioavail-
able testosterone.
Published testosterone values
Table 2 reports the pooled data from the published reports. On
average, there is little testosterone (,1 nmol/L) found in males
before the age of 10 years, at which point the levels begin to rise.
Between 10 and 15 years of age, the plasma testosterone levels
increase nearly seven-fold. The rate of increase slows as the males
reach adult levels (,15 nmol/L) between age 16 and 17 years.
These values are similar to those obtained from the ALSPAC
sample (Table 1). Table 3 reports the pooled data after incorpo-
rating the adjusted total testosterone values from ALSPAC.
ALSPAC: Growth Spurt and Characteristics of
Testosterone Trajectories
Eight participants with very high APHV estimates (.200
months) were excluded since these values are erroneous extrap-
olations of the model used to estimate APHV, as described
previously [19]. The mean age of growth spurt, defined as APHV,
is 159.83 months (SD: 13.33 months), with a range of 120 to 189
months (10 to 15.8 years).
The distribution of Age at Peak Testosterone Change in our
sample is bimodal (see Discussion), with peaks at 153 and 174
months (Mean: 162.87, SD: 10.42). On the other hand, values of
the Peak Testosterone Change are normally distributed (Mean:
0.63 [(nmol/L)/month], SD: 0.21).
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Measure of Average Exposure to Testosterone
We excluded the participants missing two blood samples
(n = 68) as their calculated values on this measure were lower
compared with participants missing one or none. Values from
participants missing one sample were not different from partici-
pants with all five blood samples. The values within the subgroup
of participants missing one sample, however, varied as a function
of the visit with a missing sample (n= 213; r2 = 0.08; p= 0.002). In
line with age-related increases in testosterone, participants missing
a sample from the second or third visits had higher estimates,
whereas those missing a sample from the fourth or fifth visit had
lower estimates. We used residuals from this model to estimate
corrected values (mean+residual) in this subgroup. A total of 445
participants had a measure of average exposure to testosterone
calculated (Mean: 8.63 nmol/L; SD: 2.15 nmol/L; Range: 3.34–
19.50 nmol/L). To determine if replacing undetectable values of
testosterone with the assay’s lower limit of sensitivity (see methods)
could have an effect on the results, we replaced undetectable
values with 0.01 nmol/L (in lieu of 0.28 nmol/L) and recalculated
the measure of average exposure to testosterone. A Pearson’s
correlation between values from the two calculations shows the
variable remains essentially unchanged (r = 0.995, p,0.001).
The average exposure to testosterone is associated with: (A) Age
at Peak Height Velocity (n= 437; r2 = 0.23; b =23.01; t =
211.28; p,.0001); (B) Age at Peak Testosterone Change
(n= 232; r2 = 0.39; b =23.21; t =212.03; p,.0001); (C) Peak
Testosterone Change (n= 232; r2 = 0.06; b = 0.03; t = 3.68;
p= .0003); (D) Testosterone at the 17 year visit (n= 409;
r2 = 0.28; b = 0.68; t = 12.73; p,.0001). These associations are
shown in Figure 1. Given the bimodal distribution of Age at Peak
Testosterone Change, participants were split into two groups on
this variable using 160 months as a cut-off point and the analysis
carried out with linear regression and shown in Figure 1 (B) was
repeated using a one-way ANOVA (n = 232; r2 = 0.32; t =210.42;
p,.0001). Note that the analyses related to Peak Testosterone
Change (B, C) were restricted to individuals with all five samples,
hence the lower sample size.
The means (and SDs) of the quintiles of average exposure to
testosterone were: 1st quintile: 5.92 (0.91); 2nd: 7.43 (0.29); 3rd:
8.43 (0.30); 4th 9.59 (0.39); and 5th: 11.72 (1.56) nmol/L.
Figure 2A shows participants’ testosterone trajectories, while 2B
shows testosterone-change trajectories (calculated as Testosterone
at Present Visit – Testosterone at Previous Visit) for each of the
average-testosterone quintiles. There are clear differences in the
shape of these trajectories across the average-testosterone quintiles:
participants in the fifth quintile demonstrate a rise in testosterone
relatively earlier and of greater magnitude whereas those within
the first quintile tend to experience a later and lower increase in
testosterone. A notable feature of the testosterone-change trajec-
tories is the peak, indicating when a participant’s testosterone
increased the most. Almost all participants from Quintile 5
experience an increase in testosterone-change before age 14 years,
whereas the participants in Quintile 1 experience their increase
almost exclusively after age 14 years.
Figure 3A shows testosterone trajectories by APHV quintiles,
and 3B the testosterone-change trajectories. We find early rising
and steep trajectories for early maturers (APHV Quintile 1), and
conversely, late rising and gentler trajectories for late maturers
(APHV Quintile 5). Similarly to what was seen in Figure 2B,
participants in APHV Quintile 1 experience an increase before
age 14 years, whereas those in APHV Quintile 5 experience their
increase after age 14 years. Again, note that the change trajectories
in Figure 2B and 3B show only the 232 participants with all five
blood samples.
Discussion
The quantification of testosterone in male ALSPAC participants
yield values that match with ranges reported in other studies.
Comparing Table 1 and Table 2, we see similar trends in the
mean values of total testosterone between 9 and 19 years of age.
Of the five published studies included here, the ALSPAC data
resemble the most [11,14] values reported in the two studies by
Elmlinger and Lee. Other studies report slightly lower values in
their samples between the ages of 12 to 15 years. The values across
studies may vary due to the variance in sample ages within the two
year intervals reported, as well as other factors such as ethnicities
of the participants included in a given sample [26]. Our
synthesized results combining the literature with ALSPAC may
serve as useful reference ranges for future investigations that
pertain to testosterone in typically developing male adolescents
(Table 3).
We also describe a simple measure for characterizing the
average exposure to testosterone over adolescence based on
longitudinal measures. We use an integral to derive this measure
instead of the arithmetic mean; the latter would bias the estimates
if the samples were clustered towards the beginning or end of
adolescence. Using the integral of a fitted spline helps minimize
this bias.
This measure is associated with timing of the pubertal growth
spurt and several characteristics of testosterone trajectories: the age
and magnitude of the rise in testosterone, and testosterone levels at
the end of the trajectory. Participants who achieve an early growth
spurt, which is known to be associated with earlier activation of the
HPG axis [27], tend to show higher averaged exposure to
Table 3. Pooled Values of Total Testosterone (nmol/L; five published studies plus the new ALSPAC data reported in this
communication).
Age # Studies n Weighted Mean (SD)
6–7 2 123 0.74 (0.15)
8–9 4 556 0.78 (0.08)
10–11 6 944 2.00 (0.46)
12–13 6 1164 8.04 (1.23)
14–15 6 1406 13.58 (1.43)
16–17 6 900 16.72 (1.68)
18–19 4 442 16.84 (1.97)
doi:10.1371/journal.pone.0108838.t003
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testosterone during puberty. Similarly, earlier and larger rises in
testosterone levels, as well as high levels of testosterone at 17 years
are all characteristics of trajectories associated with higher
averaged exposure to testosterone over the period defined by the
trajectory. Since testosterone levels remain high once they
accelerate, early and large increases in testosterone result in a
greater exposure to testosterone over puberty. These relationships
are demonstrated in Figure 1.
Differences in the shape of testosterone trajectories depicted in
Figures 2 and 3 become apparent between 160 to 180 months
indicating that possible differences in the timing of the HPG axis
activation emerge during this period. This is consistent with the
known variation in pubertal timing that is seen across the
population [28]. Note that the distribution of Age at Peak
Testosterone Change is bimodal likely because our blood samples
are taken at two-year intervals. We predict that this distribution
would be closer to normal if the frequency of sampling was
greater.
Studying testosterone trajectories in a large sample is made
challenging by circadian rhythms that cause fluctuations in
hormone levels over the time course of a day [18,29]. As such,
the time of blood draw is an important consideration in these
studies. In blood collected every 45 minutes over a course of 25.5
hours (in five healthy males), total testosterone peaked at
approximately 0500 h and 1000 h, and troughed at approximately
1400 h and 2100 h [30]. The ALSPAC blood samples were
obtained throughout the day and time of collection was not
standardized across participants and visits, thus requiring statistical
adjustment to minimize effects of the circadian rhythm on the
hormone values. This was particularly the case in data from the
third visit (Teen Focus 2; ,13 years) where a greater effect of the
circadian rhythm was observed; during this visit, time of sampling
ranged from 0900 h to 1900 h. The two preceding visits also
collected blood samples throughout the day, but the data were not
strongly affected by the circadian rhythm given the low
testosterone values present in participants at these young ages.
The data from visits at ages 15 and 17 years are not affected as
much, likely because nearly all the blood samples were taken
before the 1400 h nadir. In the first three visits, where many
participants were measured after this nadir, the time adjustment
increased their values and therefore increased the mean total
testosterone for these visits. In comparison, the last two visits have
a proportionally smaller adjustment that decreased the mean
testosterone slightly. Ideally, all participants in the study would
have been sampled at the same time of day, preferably in the
morning hours, but this was not possible for logistical reasons.
Another decision based on cost-effectiveness in a population-based
study is the use of enzyme-linked immunosorbent assays for
hormone quantification. This limits detection of very low levels of
testosterone and poses challenges when studying pre-pubertal
boys.
Testosterone, particularly its bioavailable fraction, is an
important androgen that exerts an effect on multiple biological
targets in the body. In addition to the multitude of physical
changes initiated during puberty, bioavailable testosterone has
been implicated in development and maturation of the adolescent
brain [9,10], as well as in psychopathology such as depression and
risk of psychosis [31,32]. Investigations into the effects of
hormones have usually been conducted in a cross-sectional
manner with venipuncture to collect blood for hormone quanti-
fication carried out in temporal proximity to measurement of the
outcome of interest (e.g., body composition or behavior). Inquiry
into the effect of testosterone exposure over a long time period has
rarely been conducted.
We plan to embark on such studies using data in ALSPAC,
where the database includes longitudinally collected blood samples
and measures of psychopathology throughout adolescence, in
addition to a single time-point of Magnetic Resonance Imaging in
Figure 1. Correlates of the average testosterone exposure.
Average testosterone exposure is inversely related to (A) timing of
growth spurt and (B) timing of the largest testosterone increase, but is
positively related to (C) magnitude of the largest testosterone increase
and (D) total testosterone at 17 years.
doi:10.1371/journal.pone.0108838.g001
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Figure 2. Testosterone trajectories by quintiles of the average testosterone exposure. Higher (Quintile 5) versus lower (Quintile 1) average
exposure to testosterone is associated with (A) earlier rising testosterone trajectories that remain relatively high, and (B) earlier onset and greater
magnitude of peak change in testosterone. Trajectories are plotted with adjusted testosterone values (see Methods).
doi:10.1371/journal.pone.0108838.g002
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Figure 3. Testosterone trajectories by quintiles of the growth-spurt timing. Earlier (Quintile 1) versus late (Quintile 5) growth spurt is
associated with (A) earlier rising testosterone trajectories, and (B) earlier onset of peak change in testosterone. Trajectories are plotted with adjusted
testosterone values (see Methods).
doi:10.1371/journal.pone.0108838.g003
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late adolescence to characterize brain structure and function. In
such a design, longitudinal measures can be collapsed into a
measure of average exposure and then related to an outcome
measured at the end of the study as has been done elsewhere, for
example, in the context of air pollution and cardiopulmonary
mortality [33]. Our measure of testosterone exposure over
adolescence showed associations with salient characteristics of
testosterone trajectories. In this way, we can study the effect of
testosterone dynamics on shaping the adolescent brain, and then
examine the relationship between testosterone and risk of
psychopathology. Other investigations aiming to examine longi-
tudinal effects of hormones may find utility in the measure we
describe, shown to be associated with characteristics of the
hormone trajectory.
Supporting Information
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